Advertisement
Home - Ryvu Therapeutics
Album
Contact
Developing therapeutics at the forefront of oncology About us News Releases Ryvu Therapeutics provides an update on RVU120 Phase II program Ryvu Therapeutics to Present Phase II Updates on RVU120 at Investor Event on December 12, 2024 Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) See more What we do We challenge current treatment paradigms At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology. Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs. See our Pipeline KINASE INHIBITORS Synthetic Lethality Immuno-Oncology Investor Relations Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU. Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees. See More 39.00 PLN -1.27% RVU • 23/12/2024 17:00 • Warsaw Stock Exchange Let's Grow Together Do you want to challenge and be challenged? Do you want to have an impact on the world? Please see our current openings to learn more about our work. Join Us
